Classification and clinical features of movement disorders

Movement Disorders

Volumn , Issue , 2005, Pages 1-12

  Jurkowski, Anita J ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36649038783     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088382-0/50002-5     Document Type: Chapter

References (51)

1. Adler C.H., Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology 2000, 55:S9-S14.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990, 13:266-271.
3. Anderson L.A., Hakojarvi S.L., Boudreaux S.K. Zinc acetate treatment in Wilson's disease. Ann Pharmacotherapy 1998, 32:78-87.
4. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,26-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949-956.
5. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361:1642-1644.
6. Bax R.T., Hassler A., Luck W., Hefter H., Kuageloh-Mann I., Neuhaus P., Emmrich P. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 1998, 51:863-865.
7. Bressman S.B., Raymond D., Wendt K., et al. Diagnostic criteria for dystonia in DYT1 families. Neurology 2002, 59:1780-1782.
8. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003, 60:379-385.
9. Brin M.F., Lyons K.E., Doucette J., et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001, 56:1523-1528.
10. Castillo E., Rubin R.T., Holsboer-Trachler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989, 146:324-328.
11. de Carvalho Aguiar P.M., Ozelius L.J. Classification and genetics of dystonia. Lancet Neurol 2002, 5:316-325.
12. Connor G.S. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002, 59:132-134.
13. Duvoisin R.C. A brief history of parkinsonism. Neurol Clin N Am 1992, 10:301-316.
14. Fleishschacker W.W., Unterweger B., Kane J.M., Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990, 81:3-5.
15. Gelenberg A.J. The catatonic syndrome. Lancet 1976, 1:1339-1341.
16. Gibb W.R.G., Luthert P.J., Marsden C.D. Corticobasal degeneration. Brain 1989, 112:1171-1192.
17. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404. Huntington Study Group.
18. Illarioshkin S.N., Igarashi S., Onodera O., et al. Trinucleotide repeat length and rate of progression in Huntington's disease. Ann Neurol 1994, 36:630-635.
19. Jankovic J., Orman J. Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesias. Neurology 1988, 38:391-394.
20. Jankovic J., Stacy M. Movement Disorders. Textbook of Clinical Neurology 1998, 655-679. W.B. Saunders, Philadelphia. C. Goetz, E. Pappert (Eds.).
21. Jankovic J. Tourette's syndrome. N Eng J Med 2001, 345:1184-1192.
22. Joel D., Weiner J. The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated. Neuroscience 1994, 63:363-379.
23. Krack P., Batir A., Blercom N.van, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Eng J Med 2003, 349:1925-1934.
24. Kurlan R., Como P.G., Miller B., et al. The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 50:414-420.
25. Leckman J.F. Tourette's syndrome. Lancet 2002, 360:1577-1586.
26. Louis E.D. Clinical practice: essential tremor. N Eng J Med 2001, 345:887-891.
27. Mahant N., McCusker E.A., Byth K., Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003, 61:1085-1092.
28. Mann S.C., Caroff S.N., Bleir H.R., Antelo R.E., Un H. Lethal catatonia. Am J Psychiatry 1986, 143:1374-1381.
29. Nygaard T.G., Marsden C.D., Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991, 41:174-181.
30. Ondo W., Hunter C., Vuong K.D., et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000, 15:678-682.
31. Parent A. Carpenter's Human Neuro-anatomy 1996, 795-863. Williams & Wilkins, Baltimore. Ninth Edition.
32. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996, 39(1):37-45. Parkinson Study Group.
33. Postuma R.B., Lang A.E. Hemiballism: revisiting a classic disorder. Lancet Neurol 2003, 2:661-668.
34. Reiner A., Medina L., Veenman C.L. Structural and functional evolution of the basal ganglia in vertebrates. Brain Research Reviews 1998, 28:235-285.
35. Sathornsumetee, S., and M. Stacy. (In press) Movement Disorders. In Adult Neurology. Ed. C. Bloom. St. Louis: Mosby.
36. Shill H., Stacy M. Malignant catatonia secondary to sporadic encephalitis. J Neurol Neurosurg Psychiatry 2000, 69:402-403.
37. Schuurman P.R., Bosch D.A., Bossuyt P.M., et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Eng J Med 2000, 342:461-468.
38. Stacy M., Cardoso F., Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993, 43:937-941.
39. Stacy M., Jankovic J. Tardive dyskinesia. Curr Opin Neurol Neurosurg 1991, 4:343-349.
40. Stacy M., Jankovic J. Tardive tremor. Mov Disord 1992, 7:53-57.
41. Stacy M., Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin N Am 1992, 10:341-358.
42. Stacy M., Jankovic J. Movement Disorders. Adult Neurology 1997, 267-282. Mosby, St. Louis. Second Edition. C. Bloom (Ed.).
43. Stacy M. Gilles de la Tourette's Syndrome and other tic disorders. Current Pediatric Therapy 1999, Vol 16:389-390. W.B. Saunders, Philadelphia. F.D. Burg, E.R. Wald, J.R. Ingelfinger, R.A. Polin (Eds.).
44. Stacy M. Managing late complications of Parkinson's disease. Med Clin North Am 1999, 83:469-481.
45. Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 2000, 20:9S-16S.
46. Stacy M. Progressive Supranuclear Palsy. Parkinson's Disease and Movement Disorders 2000, 229-234. Humana Press, Totowa, NJ. C.H. Adler, J.E. Ahlskog (Eds.).
47. Stacy M. Dopamine Agonists. Handbook of Parkinson's Disease 2003, Marcel-Dekker, New York. Third Edition. R. Pahwa, K. Lyons, W. Koller (Eds.).
48. Tanzi R.E., Petrukin K.K., Chernov I. The Wilson's disease gene is a copper transporting ATPase with homology to the Menke's disease gene. Nat Genet 1993, 5:344-350.
49. Vitek J.L. Pathophysiology of dystonia: a neuronal model. Mov Disord 2002, 17:S49-S62.
50. Vitek J.L., Okun M.S., Raju D.V., Walter B.L., Juncos J.L., DeLong M.R., Heilman K., McDonald W.M. Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004, 75:921-923.
51. Walker R.H., Danisi F.O., Swope D.M., et al. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 2000, 15:1242-1247.